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Abstract 
 
Bitter taste receptors TAS2Rs detect noxious compounds in the oral cavity. Recent 
heterologous expression studies reported that some compounds function as antagonists 
for human TAS2Rs. For examples, amino acid derivatives such as γ-aminobutyric acid 
(GABA) and Nα,Nα-bis(carboxymethyl)-L-Lysine (BCML) blocked responses to 
quinine mediated by human TAS2R4. Probenecid inhibited responses to 
phenylthiocarbamide mediated by human TAS2R38. In this study, we investigated the 
effects of these human bitter receptor antagonists on behavioral lick responses of mice 
to elucidate whether these compounds also function as bitter taste blockers. In 
short-term (10 s) lick tests, concentration-dependent lick responses to bitter compounds 
(quinine-HCl, denatonium and phenylthiourea) were not affected by the addition of 
GABA or BCML. Probenecid reduced aversive lick responses to denatonium and 
phenylthiourea but not to quinine-HCl. In addition, taste cell responses to 
phenylthiourea were inhibited by probenecid. These results suggest some bitter 
antagonists of human TAS2Rs can work for bitter sense of mouse. 
  





BCML, Nα,Nα-bis(carboxymethyl)-L-Lysine; CV, circumvallate papillae; Den, 
denatonium benzoate; DW, distilled water; FP, fungiform papillae; GABA, 
γ-aminobutyric acid; GIV 3727, 4-(2,2,3-trimethylcyclopentyl) butanoic acid; HEK, 
human embryonic kidney; IP3R3, inositol-1,4,5-triophosphate receptor type 3; KO, 
knockout; PLCβ2, phospholipase Cβ2; PROP, 6-n-propyl-2-thiouracil; PTC, 
phenylthiocarbamide; PTU, phenylthiourea; QHCl, quinine-HCl; MPG, monopotassium 
glutamate; SE, standard error; Tas2Rs, type 2 taste receptors; TRPM5, transient receptor 






Among the basic taste modalities, bitter taste is an aversive taste elicited by numerous 
chemically different compounds [1]. Many noxious and poisonous compounds have a 
bitter taste, therefore the bitter taste is thought to play an important role in protecting 
from ingestion of these noxious compounds. Although more than 1,000 compounds 
have a bitter taste, only a limited number of receptors detect these compounds. The 
bitter receptors, type 2 taste receptors (TAS2Rs), comprise a G-protein-coupled receptor 
family, which includes 25 and 35 functional receptors in humans and mice, respectively 
[2-6]. Binding of bitter compounds to a TAS2R elicits activation of intracellular 
signaling cascades in taste cells, including α-gustducin [7], phospholipase Cβ2 (PLCβ2) 
[8], inositol-1,4,5-triophosphate receptor type 3 (IP3R3) [9] and transient receptor 
potential channel M5 (TRPM5) [8], leading to depolarization and generation of action 
potentials in taste cells [10, 11]. 
The agonists of each bitter receptor have been determined by functional expression 
assays. The first report demonstrated that human embryonic kidney (HEK) cells 
expressing mouse Tas2r5 (Tas2r105) responded to cycloheximide [3]. The same report 
also showed that human TAS2R4 and mouse Tas2r8 (Tas2r108) responded to 
denatonium and high concentrations of 6-n-propyl-2-thiouracil (PROP). Functional 
expression assays for bitter receptors also revealed the molecular basis for the 
differences in bitterness recognition of phenylthiocarbamide [PTC, also known as 
phenylthiourea (PTU)], which was explained by single nucleotide polymorphisms 
(SNPs) in the human TAS2R38 gene [12, 13]. More recent high throughput assays have 
determined the molecular receptive ranges of human and mouse bitter receptors [14, 15]. 
Thus, our knowledge of cognate agonists for bitter receptors is gradually increasing, but 
further studies are required to fully elucidate the ligands of each of the bitter receptors.  
Antagonists of bitter taste receptors may be useful for suppressing the bitter taste and 
may help in ingesting bitter tasting drugs. Similar to bitter agonists, some bitter 
antagonists have been identified by functional expression assays. The first reported 
antagonist was the small molecule, 4-(2,2,3-trimethylcyclopentyl) butanoic acid 
(GIV3727), which suppresses the activation of human TAS2R31 [16]. Subsequently, 
probenecid [17], sesquiterpene lactones [18], 6-methoxyflavanones [19], γ-aminobutyric 
acid (GABA) and Nα,Nα-bis(carboxymethyl)-L-Lysine (BCML) [20] have been 
identified as antagonists of human TAS2Rs. Although some bitter antagonists have been 
shown to inhibit cat and chicken bitter receptors [21, 22], it is unclear whether bitter 
antagonists also function and affect bitter sensitivity in non-human species. 
In this study, we investigated the effects of the bitter antagonists, GABA, BCML and 
probenecid on behavioral lick responses of mice to multiple tastants, to reveal whether 
these bitter antagonists block perception of bitterness in mice. 
 
Material and Methods 
 
Animals 
All experimental procedures were performed in accordance with the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals and approved by the 
committee for Laboratory Animal Care and Use at Kyushu University and Okayama 
University, Japan. Subjects were adult C57BL6/J (>8 weeks old) male mice. All mice 
were housed under a 12:12-h light-dark cycle (lights on 0800-2000h) and had ad libitum 
access to tap water and food pellets (CE-2, CLEA Japan, Tokyo, Japan). Mice were 
divided into two groups: one for testing the effect of GABA and BCML (n = 9), and one 
for testing the effect of probenecid (n = 10). Gustducin-GFP mice [23] were used for 
recording of taste cell responses. 
 
Solutions 
Taste stimuli used were as follows (mM): 10–1000 NaCl, 10–1000 sucrose, 1–30 HCl, 
10–300 monopotassium glutamate (MPG), 0.01–3 quinine-HCl (QHCl), 0.1–3 
denatonium benzoate (Den), and 0.3–10 phenylthiourea (PTU). Tastants were dissolved 
in distilled water (DW) and used at room temperature (25°C). These concentrations of 
tastants were used in previous studies [24, 25]. To test the effect of GABA and BCML, 
1/1000 volume of 100 mM GABA (final concentration: 100 µM) or 10 mM BCML 
(final concentration: 10 µM) was added to these solutions [20]. To test the effect of 
probenecid, 1/1000 volume of 1 M probenecid dissolved in 1 N NaOH (final 
concentration: 1 mM probenecid) or 1/1000 volume of 1 N NaOH (for control) was 
added to these solutions [16]. In the probenecid group, HCl was not assessed because of 
the precipitation of probenecid by acids. All chemicals were purchased from Sigma–
Aldrich (St. Louis, MO, USA) or Wako Pure Chemical Industries (Osaka, Japan). 
 
Short term lick test 
Taste behavior was assessed using a short term (10 s) lick test [24]. On the first day of 
training, each animal was water deprived for 23 h, then placed in the test cage and given 
free access to DW during the 1 h session. Day 2-5 were training sessions. During this 
period, the animal was trained to drink DW on an interval schedule, consisting of 10-s 
periods of DW presentation alternating with 20-s inter-trial intervals. From day 6, the 
number of licks for each taste solutions and DW was counted during the first 10 s after 
the animal’s first lick using a lick meter (Yutaka Electronics Co. Gifu, Japan). On each 
test day, the first test stimulus given to the animal was DW. Then, test stimuli were 
tested in a randomized order. After bitter tastants (QHCl, Den and PTU) were tested, 
other tastants or DW were tested to avoid successive application of bitter solutions. The 
schedule for testing the effect of GABA and BCML was as follows: days 6, 11 and 13 
for control taste solutions; days 7, 9 and 14 for taste solutions + GABA; days 8, 10 and 
12 for taste solutions + BCML. The schedule for testing the effect of probenecid was as 
follows: days 6, 9 and 10 for control taste solutions with NaOH; days 7, 8 and 11 for 
taste solutions + probenecid. The mean number of licks across three days by each 
animal was used for statistical analysis. 
 
Taste cell recording 
Recording procedures were similar to those used previously [26]. Briefly, the tongue 
were removed and treated with 0.5 mg/ml elastase (Elastin Products, Owensville, MO, 
USA). Then, the lingual epithelium was peeled and individual taste buds with a piece of 
surrounding epithelium were excised and set to the stimulating pipette. Taste stimuli 
were applied to the apical membrane via stimulating pipette. Tyrode solution (140 NaCl, 
5 KCl, 1 CaCl2, 1 MgCl2, 5 NaHCO3, 10 HEPES, 10 Glucose, 10 sodium pyruvate in 
mM; pH = 7.4 with NaOH) was continuously flowed into the recording chamber. GFP 
taste cells were identified by confocal laser scanning microscopy (FV-300; Olympus, 
Tokyo, Japan) and were approached by a recording electrode. Electrical signals were 
recorded by a high-impedance patch-clamp amplifier (Axopatch 200B; Axon 
Instruments, Foster City, CA, USA) interfaced to a computer (Windows 7) by an 
analog-to-digital board (Digidata 1440A; Axon Instruments).  
 
Data analysis 
Two-way or one-way repeated ANOVA with post hoc Holm test was used to statistically 
evaluate the effect of GABA, BCML and probenecid. All statistical calculations were 
performed using the EZR program on Windows 10 [27]. All summarized data are 





The effect of GABA and BCML on lick responses to tastants 
GABA and BCML have been reported to inhibit responses to quinine in HEK cells 
expressing human TAS2R4 [20]. Therefore, we tested whether the addition of GABA or 
BCML to bitter solutions disturbs bitter perception in mice. Mice showed a 
concentration-dependent avoidance from the bitter compounds, QHCl, Den and PTU in 
the short-term lick tests (Fig. 1). This concentration-dependent avoidance from bitter 
compounds was not affected by the addition of 100 µM GABA or 10 µM BCML (Fig. 
1). The mean lick rates for QHCl, Den and PTU were not significantly different 
between the control, GABA and BCML treatments (Supplemental table 1). We also 
tested whether GABA or BCML affects the lick responses to other tastants. The mean 
lick rates for sucrose (sweet), NaCl (salt), MPG (umami) and HCl (sour) were not 
significantly different between the control, GABA and BCML treatments (Fig. 2, 
Supplemental table 1). Taken together, addition of GABA or BCML to taste solutions 
did not appear to affect taste perception in mice. 
 
The effect of probenecid on lick responses to tastants 
Probenecid is another bitter antagonist reported to inhibit human TAS2R16, 38 and 43 
[17]. Next, we tested whether the addition of probenecid to bitter solutions affects lick 
responses to bitter solutions in mice. In contrast to GABA and BCML, probenecid 
reduced avoidance from Den and PTU in the short-term lick tests (Fig. 3). The mean 
lick rates for Den and PTU were significantly different between the control and 
probenecid treatments (Fig. 3B, C, Supplemental table 2). However, the lick responses 
to QHCl were not affected by the addition of probenecid (Fig. 3A, Supplemental table 
2). The mean lick rates for sucrose, NaCl, and MPG were not significantly different 
between the control and probenecid treatments (Fig. 4, Supplemental table 2). These 
results suggest that probenecid inhibits some mouse bitter receptors contributing to the 
detection of Den and PTU. 
 
Taste cell responses 
We tested whether probenecid inhibits taste cell responses to PTU. Responses of 
Gustducin-GFP taste cells to 10 mM PTU were inhibited by the addition of 1 mM 




More than 1,000 chemical compounds have bitter tastes in humans, but only a small 
number of compounds have been reported to function as bitter antagonists. The effects 
of bitter antagonists have been analyzed by heterologous expression studies of human 
TAS2Rs [16-20]. In this study, we investigated mainly by behavioral tests whether some 
of bitter antagonists have a similar effect on mouse bitter receptors. We used the 
effective concentrations of bitter antagonists that have been reported in previous 
heterologous expression studies [17, 20]. At the tested concentrations, these antagonists 
did not elicit a taste or change preferences for lick responses of mice, as the addition of 
each antagonist did not affect both the preferable (sucrose) and aversive (HCl, QHCl) 
responses (Figs. 1–4). We found that the human TAS2R4 antagonists, GABA and 
BCML, had no effect on taste perception in mice (Fig. 1, 2). These results are consistent 
with previous studies of taste cell responses [26]. Thus, similarly to bitter agonists [15], 
some bitter antagonists (GABA and BCML) may have different efficiencies among 
species. Differences in the effects of taste receptor antagonists among species have also 
been reported for sweet taste: gymnemic acids inhibit human, but not mouse, sweet 
receptors [28-30]. The species-specific effect of gymnemic acids depends on the amino 
acid changes in the sweet receptor component, Tas1R3, between humans and mice [31]. 
Therefore, amino acid changes between human TAS2R4 and its ortholog mouse 
Tas2r108 may account for the different effect of GABA and BCML on human and 
mouse bitter receptors. The important residues for the effect of GABA and BCML have 
been reported to be Ala-82 and Lys-262 in human TAS2R4 [20]. The corresponding 
residues in mouse Tas2r108 are substituted by Thr and Gln, respectively. These amino 
acid changes may cause less or no binding of GABA and BCML to mouse Tas2r108. 
Additionally, methodological differences may contribute to the different results. In the 
heterologous expression experiments, the analyzed cells expressed a specific bitter 
receptor, such as human TAS2R4, and the effect of antagonists on the specific receptor 
was analyzed. However, in the behavioral tests, tested mice possess multiple types of 
bitter receptors including mouse Tas2r108. If the effect of GABA and BCML is specific 
to mouse Tas2r108, activation of other bitter receptors by bitter agonists [15] may 
neutralize the effect of bitter antagonists at the behavioral level. To our knowledge, the 
effects of GABA and BCML on bitter receptors other than human TAS2R4 have not 
been tested. 
We also found that probenecid significantly reduced aversive lick responses to Den and 
PTU, but not to QHCl in mice. Probenecid blocked activation of human TAS2R16, 38 
and 43 [17]. These human bitter receptors have been reported to respond to Den (human 
TAS2R43), PTU (human TAS2R38) and QHCl (human TAS2R43) [14]. The mouse 
orthologs of human TAS2R16 and 38 are mouse Tas2r118 and 138, respectively. 
However, there is no mouse ortholog of human TAS2R43. Mouse Tas2r138 responded 
to 5-propyl-2-thiouracil and Yohimbin, whereas agonists of mouse Tas2r118 were not 
determined, although it is quite abundantly expressed in taste tissues [15]. In a 
heterologous expression study, a bitter receptor for PTC was not determined when it 
was used at 0.1 mM [15]. Our results showed that aversion to PTU was observed at 
higher concentration (3–10 mM) and taste cells were activated by 10 mM PTU, namely, 
mouse Tas2r138 was activated by high concentrations of PTC (PTU). Taken together, 
the blockade of mouse Tas2r138 by probenecid may lead to reduced aversive responses 
to PTU. Conversely, reduction in aversive responses to Den may not be explained by 
blockade of mouse Tas2r138 because this receptor was not activated by Den in 
heterologous expression experiments [15]. Probenecid may inhibit mouse Tas2r118 or 
other Tas2rs [15], leading to reduction in aversive responses to Den. Probenecid has 
been shown to inhibit human and cat Tas2R38 and 43 [21]. Taken together, probenecid 
may be used as a common antagonist of PTU bitter receptors in humans, cats and mice. 
Probenecid is an allosteric antagonist that targets the intracellular part of several human 
TAS2Rs [17], whereas the other antagonists are assumed to target the orthosteric 
TAS2R binding site, which has been demonstrated for GIV3727 [16, 18]. Because the 
intracellular part of TAS2Rs is more conserved than the extracellular part [32], it is 
reasonable to assume that probenecid shows cross-species activity compared with the 
other antagonists.  
 
Conclusion 
In this study, we revealed that the efficacy of some bitter antagonists (GABA and 
BCML) may be different among species. Additionally, we demonstrated the consistent 
effect of the bitter antagonist, probenecid, on human and mouse PTC bitter taste 
receptors. Bitter antagonists are powerful tools for investigating the function of bitter 
taste receptors. However, such differences should be considered when these antagonists 
are used in both in vivo and in vitro studies. Further studies are required to reveal the 
molecular mechanisms that underlie the similarities and differences in the effects of 
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Fig. 1. The effect of addition of GABA and BCML on lick responses to bitter 
compounds. Concentration-dependent lick responses to quinine (A), denatonium (B) 
and PTU (C) with or without 100 µM GABA or 10 µM BCML in mice (n = 9). All data 
are presented as the mean ± SE. 
 
Fig. 2. The effect of addition of GABA and BCML on lick responses to sweet, salty, 
umami and sour compounds. Concentration-dependent lick responses to sucrose (A), 
NaCl (B), MPG (C) and HCl (D) with or without 100 µM GABA or 10 µM BCML in 
mice (n = 9). All data are presented as the mean ± SE. 
 
Fig. 3. The effect of addition of probenecid on lick responses to bitter compounds. 
Concentration-dependent lick responses to quinine (A), denatonium (B) and PTU (C) 
with or without 1 mM probenecid in mice (n = 10). All data are presented as the mean ± 
SE. +: P<0.05, +++: P<0.001, two-way ANOVA. *: P<0.05, post hoc Holm test. 
 
Fig. 4. The effect of addition of probenecid on lick responses to sweet, salty and 
umami compounds. Concentration-dependent lick responses to sucrose (A), NaCl (B), 
MPG (C) and HCl (D) with or without 1 mM probenecid in mice (n = 10). All data are 
presented as the mean ± SE. 
 
Fig. 5. The effect of probenecid on taste cell responses to PTU. Sample recordings (A) 
and individual data (B) showing the effect of 1 mM probenecid (+proben) on PTU 
responses of gustducin-GFP taste cells (n=5, F=9.0, P<0.01, One-way repeated 
ANOVA). 
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  Interaction 6, 96 0.472 
**: P<0.01, ***: P<0.001 
 





QHCl Additive 1, 90 0.638 
 
Concentration 4, 90 109.5*** 
  Interaction 4, 90 0.49 
Den Additive 1, 72 86.5*** 
 
Concentration 3, 72 4.874* 
  Interaction 3, 72 1.597 
PTU Additive 1, 72 12.8*** 
 
Concentration 3, 72 31.4*** 
  Interaction 3, 72 4.415** 
Sucrose Additive 1, 90 0.408 
 
Concentration 4, 90 1.091 
  Interaction 4, 90 0.162 
NaCl Additive 1, 90 1.432 
 
Concentration 4, 90 292.9*** 
  Interaction 4, 90 0.206 
MPG Additive 1, 72 0.326 
 
Concentration 3, 72 1.076 
  Interaction 3, 72 0.122 
*: P<0.05, **: P<0.01, ***: P<0.001 
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